

Aminex Therapeutics

Aminex Therapeutics Appoints David Meek to Board of Directors as Executive Chairman

September 3, 2024, Seattle, WA – [Aminex Therapeutics, Inc.](#), a private clinical-stage biotechnology company focused on advancing a novel cancer immunotherapy, today announced the appointment of David Meek as a Director and Executive Chairman.

Mr. Meek brings more than thirty years of experience leading biotechnology companies including executive leadership and board-level positions in biopharmaceutical and commercial-stage biotechnology companies focused on oncology.

Most recently, Mr. Meek served as Chief Executive Officer and Board Director of Mirati Therapeutics, a public oncology biotechnology company, from 2021 to 2023. Mirati was acquired by Bristol-Myers Squibb for \$5.8 billion. He previously served as Chief Executive Officer, Founder and Board Director of FerGene, Inc., a private oncology gene therapy biotechnology company. Mr. Meek also served as Chief Executive Officer and Board Director of Ipsen, a public biopharmaceutical company based in France. Prior to joining Ipsen, Mr. Meek held executive leadership roles including serving as Executive Vice President and President of Oncology at Baxalta leading up to the \$32 billion acquisition by Shire and serving as Chief Commercial Officer of Endocyte. He also served in global and general management executive roles at Novartis Pharmaceuticals and Novartis Oncology. He began his biopharmaceutical career with Johnson & Johnson's Janssen Pharmaceuticals. He currently serves on the board of directors of uniQure N.V., and Cullinan Therapeutics, both public biotech companies. He previously served on the board of directors of Fusion Pharmaceuticals until its acquisition by AstraZeneca for \$2.4 billion in June 2024 and Entasis Therapeutics until its acquisition by Innoviva, Inc. in 2022. He also serves on the board of the University of

Southern California Mann School of Pharmacy and Pharmaceutical Sciences. Mr. Meek served on the industry boards of Pharmaceutical Research & Manufacturers of America (PhRMA) and European Federation of Pharmaceutical Industries & Associations (EFPIA).

"We are thrilled to have David join the Aminex board and team at this exciting time in the company's trajectory and know his breadth of oncology strategic, clinical development and partnering experience will be invaluable as we advance our novel immunotherapy treatment," said Stacy Hock, immediate past Executive Chairman and current Director on the Aminex Board of Directors.

"David has a proven track record in the successful advancement of oncology assets through the clinical development stage, and we look forward to the impact we know he will make," said Mark Burns, PhD, President and Chief Science Officer

"Aminex has developed and advanced a novel and potential first in class oncology asset with compelling preclinical and clinical results," said Mr. Meek. "I look forward to contributing to the rapid clinical development of AMXT 1501 for people living with cancer.

About Aminex Therapeutics

Aminex Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of a novel small molecule combination immunotherapy for the treatment of cancer. Aminex' immunotherapy approach combines the company's investigational oral, small molecule polyamine uptake inhibitor, AMXT 1501, with the polyamine synthesis inhibitor, DFMO, that is FDA approved. AMXT 1501 is designed to work in conjunction with DFMO to constrain the production *and* uptake of polyamines – molecules found in high concentrations in cancer cells and linked to immune system suppression. Reducing polyamines and, in turn, decreasing myeloid-derived suppressor cells in the tumor microenvironment, allows for activation of the immune system to attack solid tumors. Aminex is exploring multiple rational combination approaches to treat cancer. Aminex has advanced AMXT 1501 through target discovery, patenting, pre-clinical research and into clinical development for the potential benefit of people with cancer.

For more information, please visit www.aminextx.com.

#

Media Contact:

Julie Rathbun
Rathbun Communications
Julie@rathbuncomm.com
206-769-9219